HLA-B*40:01 Is Associated with Ankylosing Spondylitis in HLA-B27-positive Populations

To the Editor:

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that primarily involves the axial skeleton and the sacroiliac joints. The susceptibility to AS is almost entirely attributable to genetic factors; their heritability is estimated at around 90%¹. The MHC class I is the most significant genetic region for the disease, and most of its genetic association is driven by HLA-B27². There is evidence suggesting that the presence of other HLA-B alleles, including B*14, B*38, B*39, B*40, and B*52, may also confer greater susceptibility to AS³. A recent study examined HLA loci associations of AS genotyping of 7264 MHC single-nucleotide polymorphisms (SNP), in 9069 affected individuals and 13,578 controls⁴. Genotyping data were followed by imputation of SNP, classical HLA alleles, and residues at polymorphic amino acid positions of HLA proteins. In addition to HLA-B*27, the association was identified with B*13:02, B*40:01, B*40:02, B*47:01, and HLA-B*51:01 (risk alleles); and B*07:02 and B*57:01 (protective alleles).

We examined the distribution of HLA-B alleles in patients with AS and control subjects in a Spanish population previously described by our group^{5,6}. A total of 1300 individuals were studied as 3 distinct cohorts. Cohort 1 comprised 462 healthy controls who were HLA-B27-negative; cohort 2 included 367 patients with AS; and cohort 3 consisted of 549 controls who were HLA-B27-positive. The patients with AS were diagnosed following New York criteria⁷. All individuals gave written informed consent prior to enrolling in the study. The protocol was approved by the ethics committee of the Hospital Universitario Central de Asturias, Spain, and conducted according to the Declaration of Helsinki.

Table 1 shows the distribution of HLA-B alleles in controls (B*27-negative and B*27-positive) and patients with AS (B*27-negative and B*27-positive). We have confirmed the well-established association of AS with HLA-B27, occurring in 86.7% of AS cases. No significant

difference was observed between the frequencies of B*27 subtypes in HLA-B27-positive populations (AS patients and controls). When we compared all patients with AS to controls who were B*27-negative, we observed results similar to those found in Cortes, *et al*⁴. B*07:02 and B*57:01 allele frequencies were significantly decreased in patients with AS compared to healthy controls (9.5% vs 18.8%, $P_{\text{BONF}} < 0.01$, OR 0.45, 95% CI 0.30–0.70; 2.7% vs 7.8%, 2-tailed Fisher's exact test $p < 0.005$, OR 0.33, 95% CI 0.16–0.68; respectively). In addition, carriage of B*44 and B*51:01 was also significantly decreased in patients with AS compared to controls (14.4% vs 30.1%, $P_{\text{BONF}} < 10^{-5}$, OR 0.39, 95% CI 0.28–0.56; 8.7% vs 16.9%, $P_{\text{BONF}} < 0.05$, OR 0.47, 95% CI 0.30–0.73; respectively).

When we analyzed only B27-positive patients with AS and B27-positive control subjects, all these differences disappeared. However, the HLA-B*40:01 allele was significantly increased in B*27-positive patients with AS compared with B*27-positive controls ($P_{\text{BONF}} < 0.001$, OR 23.36, 95% CI 3.04–179.42). In addition, B*38:01 allele frequency was significantly increased in patients with AS who were B27-negative compared to B27-negative controls (20.4% vs 4.6%, $P_{\text{BONF}} < 0.01$, OR 5.38, 95% CI 2.37–12.24).

Previous findings identified a strong association between ERAP1 and AS that is restricted to HLA-B*27-positive disease⁸. The study conducted by Cortes, *et al* showed that HLA-B*40:01 interacts with ERAP1 in the same manner⁴. Several studies have suggested that HLA-B*40:01 is another HLA-B allele operative in AS susceptibility, in US and UK patients with AS³. Wei, *et al* reported that B*40:01 is a risk factor for HLA-B27-negative AS in Taiwan Chinese⁹, suggesting that the effect of this allele could be different in non-white patients. In our study, HLA-B*40:01 association with AS is confirmed in HLA-B27 white populations. All these data provided evidence that HLA-B operates in AS through a mechanism involving aberrant processing of antigenic peptides. Moreover, the association across ethnic groups suggests that the association is directly with HLA-B*40:01, rather than any other gene in linkage disequilibrium with it, although further studies will be required to confirm this.

Table 1. Phenotype frequencies in HLA-B antigens in patients with AS and control groups, stratified by HLA-B27 positivity.

CONT B27-negative, N = 462			AS, N = 367		CONT B27-positive, N = 549		AS B27-positive, N = 318		AS B27-negative, N = 49	
HLA-B allele	n	%	n	%	n	%	n	%	n	%
B*27:02	0	0.00	22	5.99	19	3.46	22	6.92	0	0.00
B*27:04	0	0.00	1	0.27	0	0.00	1	0.31	0	0.00
B*27:05	0	0.00	293	79.84	531	96.72	293	92.14	0	0.00
B*27:08	0	0.00	2	0.54	0	0.00	2	0.63	0	0.00
B*07:02 ^a	87	18.83	35	9.54	53	9.65	27	8.49	8	16.33
B*08:01	71	15.37	36	9.81	44	8.01	30	9.43	6	12.24
B*13:02	7	1.52	7	1.91	10	1.82	5	1.57	2	4.08
B*14	55	11.90	29	7.90	46	8.38	23	7.23	6	12.24
B*18:01	62	13.42	21	5.72	34	6.19	18	5.66	3	6.12
B*38:01 ^f	21	4.55	18	4.90	12	2.19	8	2.52	10	20.41
B*39	5	1.08	5	1.36	10	1.82	4	1.26	2	4.08
B*40:01 ^e	19	4.11	17	4.63	1	0.18	13	4.09	4	8.16
B*40:02	7	1.52	4	1.09	4	0.73	2	0.63	2	4.08
B*44 ^c	139	30.09	53	14.44	69	12.57	40	12.58	13	26.53
B*47	4	0.87	4	1.09	3	0.55	4	1.26	0	0.00
B*51:01 ^d	78	16.88	32	8.72	40	7.29	21	6.60	11	22.45
B*52	11	2.38	5	1.36	6	1.09	5	1.57	0	0.00
B*57:01 ^b	36	7.79	10	2.72	27	4.92	8	2.52	1	2.04
All other alleles	298	64.50	139	37.87	185	33.70	108	33.96	29	59.18

AS versus CONT: ^a 9.5% vs 18.8%, $P_{\text{BONF}} < 0.01$, OR 0.45, 95% CI 0.30–0.70. ^b 2.7% vs 7.8%, $P_c < 0.005$, OR 0.33, 95% CI 0.16–0.68. ^c 14.4% vs 30.1%, $P_{\text{BONF}} < 10^{-5}$, OR 0.39, 95% CI 0.28–0.56. ^d 8.7% vs 16.9%, $P_{\text{BONF}} < 0.05$, OR 0.47, 95% CI 0.30–0.73. AS B27-positive vs CONT B27-positive: ^e 4.1% vs 0.2%, $P_{\text{BONF}} < 0.001$, OR 23.36, 95% CI 3.04–179.42. AS B27-neg versus CONT: ^f 20.4% vs 4.6%, $P_{\text{BONF}} < 0.01$, OR 5.38, 95% CI 2.37–12.24. AS: ankylosing spondylitis; P_{BONF} : P value using Bonferroni correction; P_c : 2-tailed Fisher's exact test; CONT: controls.

Although few samples were analyzed, a strong association of AS with HLA-B*38:01 was seen in HLA-B*27-negative populations. Other studies such as Cortes, *et al* have not reported this association⁴. It would be interesting to investigate the HLA-B distribution in AS populations in countries where the influence of B*27 is lower, such as African and Latin American countries¹⁰. Further research is required to clarify the role of the HLA-B locus in this disease.

ROBERTO DÍAZ-PEÑA, PhD, Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain, and Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile; JOSE RAMÓN VIDAL-CASTIÑEIRA, PhD, Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain; ANTONIO LÓPEZ-VÁZQUEZ, MD, Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain; CARLOS LÓPEZ-LARREA, PhD, Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain. Address correspondence to C. López-Larrea, Department of Immunology, Hospital Universitario Central de Asturias, C/ Celestino Villamil s/n, 33006-Oviedo, Spain. E-mail: inmuno@hca.es Supported by Fondecyt grant no. 11130198, and in part by the Spanish grants: Instituto de Salud Carlos III (PI12/02587); Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (GRUPIN 14-030), and the European Fondos Feder.

REFERENCES

1. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. *Arthritis Rheum* 1997;40:1823-8.
2. Robinson PC, Brown MA. Genetics of ankylosing spondylitis. *Mol Immunol* 2014;57:2-11.
3. Díaz-Peña R, López-Vázquez A, López-Larrea C. Old and new HLA associations with ankylosing spondylitis. *Tissue Antigens* 2012;80:205-13.
4. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. *Nat Commun* 2015;6:7146.
5. Díaz-Peña R, Aransay AM, Bruges-Armas J, López-Vázquez A, Rodríguez-Ezpeleta N, Mendibil I, et al. Fine mapping of a major histocompatibility complex in ankylosing spondylitis. *Arthritis Rheum* 2011;63:3305-12.
6. Díaz-Peña R, Aransay AM, Suárez-Álvarez B, Bruges-Armas J, Rodríguez-Ezpeleta N, Regueiro M, et al. A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:714-7.
7. Van de Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361-8.
8. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet* 2011;43:761-7.
9. Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. *Rheumatology* 2004;43:839-42.
10. Benegas M, Muñoz-Gomariz E, Font P, Burgos-Vargas R, Chaves J, Palleiro D, et al. Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America. *J Rheumatol* 2012;39:2315-20.

J Rheumatol 2016;43:6; doi:10.3899/jrheum.151096